TIMP2 and chronic kidney disease: Moreover, we wanted to establish the clinical and biochemical parameters that may influence the systemic MMP-2 and TIMP-2 levels both in β-blocker-treated [β-blockers (+)] and untreated [β-blockers (−)] patients with CKD.